Objective. Oxycodone DETERxV R is an extendedrelease (ER), microsphere-in-capsule abuse-deterrent-formulation designed to retain its extendedrelease properties following tampering or misuse (e.g., chewing, crushing). This study assessed the safety and pharmacokinetics of orally administered intact and crushed Oxycodone DETERxV R capsules compared with intact and crushed reformulated OxyContinV R tablets and crushed immediate-release oxycodone tablets (IR oxycodone).
Methods. This was a randomized, open-label, active-controlled, cross-over study. Healthy subjects received five oxycodone treatments (40 mg) with a standardized high-fat, high-calorie meal: Oxycodone DETERxV R (intact or crushed), OxyContinV R (intact or crushed), and IR oxycodone (crushed). Blood samples were collected for assessment of oxycodone plasma concentrations.
Results. Thirty-eight subjects completed the study. Both crushed and intact Oxycodone DETERxV R resulted in lower peak plasma concentrations when compared with IR oxycodone. Crushed Oxycodone DETERxV R was bioequivalent to intact Oxycodone DETERxV R and exhibited a numerically lower C max . Also, median T max was unchanged by crushing. In contrast, mean peak plasma oxycodone concentrations for crushed OxyContinV R were significantly higher compared with intact OxyContinV R and were bioequivalent to IR oxycodone. Median T max for crushed OxyContinV R was the same as IR oxycodone and 3.25 hours shorter than intact OxyContinV R .
Conclusions. These data demonstrate that when crushed and taken orally, Oxycodone DETERxV R maintains its EXTENDED-release profile, while crushed OxyContinV R shows a pharmacokinetic profile similar to an immediate-release product. These results suggest that Oxycodone DETERxV R may be less attractive to illicit drug users compared with existing abusedeterrent-formulations, while providing a safer option for patients who may unknowingly crush their medication such as those who have difficulty swallowing.
Introduction
The use of opioids to treat chronic pain has increased substantially over the past few years [1, 2] ; when used as prescribed, opioid analgesics can improve quality of life for patients suffering from chronic pain. However, as the medical use of opioids increased, so have the reported rates of misuse, abuse, and subsequent drugrelated deaths [3] [4] [5] . In 2013, approximately 4.5 million individuals aged 12 and older reported past month nonmedical use of prescription opioids [6] , while emergency department visits associated with abuse or misuse of opioids in the United States increased from an estimated 172,738 in 2004 to an estimated 488,004 in 2011. This amounts to an 183% increase in less than 10 years [7] . More recent data suggest that abuse of prescription opioids may be stabilizing or decreasing due to a number of possible factors including decreases in the number of prescriptions filled, the introduction of abuse-deterrent opioid formulations (ADFs) and local, state, and federal programs to improve opioidprescribing practices [8, 9] . Although abuse-related concerns associated with chronic opioid therapy are critical, care must be taken not to deprive those patients in pain who have a legitimate medical need for opioid analgesics.
Extended-release (ER) opioid formulations offer several clinical advantages including the convenience of less frequent dosing, decreased fluctuations in plasma levels, more consistent analgesia over the dosing period, and less night-time awakening due to pain [10, 11] . Although ER formulations offer numerous clinical benefits, they are at particular risk for abuse via unintended routes because they contain higher amounts of the active drug compared with immediate-release (IR) formulations. When most ER formulations are altered or tampered with (e.g., by crushing or chewing), much, if not all of the active drug can be released more rapidly. This rapid onset increases the positive subjective and euphoric effects or "high" of an abusable drug, and consequently increases the attractiveness of such a drug for abuse [12] .
A number of risk management approaches have been recommended to mitigate prescription opioid abuse and misuse, one of which is the development of ADFs designed to discourage abuse via specific routes of administration, while preserving analgesic benefits for patients [13, 14] . In 2013, the US Food and Drug Administration (FDA) released a draft guidance document on the evaluation of abuse-deterrent opioids, which outlines the studies that should be conducted during development and following approval of these agents. This guidance was finalized in April of 2015. The studies outlined in the guidance are broken down into four categories and include laboratory-based in vitro manipulation (mechanical) and extraction (chemical) studies, pharmacokinetic studies to build on the manipulation or extraction data collected from in vitro studies, clinical abuse potential studies, also known as human abuse potential (HAP) or human abuse liability (HAL) studies, and postmarketing studies to identify whether the potential ADF results in a significant and persistent decrease in abuse once marketed.
A number of approaches can be taken in the development of ADFs; the guidance briefly outlines the different classifications, commonly categorized as physicalbarrier, agonist-antagonist, aversion, or prodrug [15, 16] . Physical-barrier or physicochemical formulations include properties that render the product difficult to crush or chew. These formulations, which often include excipients that result in larger and harder tablets, are effective in deterring illicit use, while also protecting patients with chronic pain who may mistakenly crush, break, and/or grind their opioid analgesics to facilitate swallowing the tablet or capsule [17] . However, there are a number of patients with chronic pain using opioids who have difficulty swallowing tablets and capsules and must resort to manipulation of the dosage form to successfully ingest their medication. The currently available physicochemical ADFs (e.g., reformulated OxyContinV R [Purdue Pharma, LP, Stamford, CT]) do not address the need for a dosage form that can be administered via alternate routes such as cutting the tablet into small pieces or sprinkling onto food, while still retaining abuse deterrent properties, and these ADFs usually lose a substantial proportion of their ER properties when ground or crushed [18] .
Oxycodone DETERxV R (Collegium Pharmaceutical, Inc., Canton, MA) is an ER, microsphere-in-capsule formulation, designed to retain its ER properties following common tampering methods. The small particle size of Oxycodone DETERxV R microspheres also allows for clinical advantages such as administration via enteral tube or by sprinkling onto soft food, thereby enabling a continuum of care for patients who initially can consume oral capsules, but subsequently develop swallowing difficulty, which may occur with a variety of clinical conditions or disease states.
Two recent studies were completed with Oxycodone DETERxV R . The first examined the most effective tampering approaches for Oxycodone DETERxV R (in vitro manipulation study) and the second, an in vivo study, evaluated the impact of the most aggressive mechanical manipulation methods and chewing on the pharmacokinetics of Oxycodone DETERxV R . Results of these studies revealed that despite aggressive manipulation, Oxycodone DETERxV R microspheres retained their ER properties in both a fed and fasted state [19] .
The purpose of this study was to compare the pharmacokinetics and safety (under naltrexone blockade) of intact and crushed Oxycodone DETERxV R with intact and crushed reformulated OxyContinV R when both products are administered with food and to compare both with crushed IR oxycodone, also administered with food. In this study, the pharmacokinetic profile of Oxycodone DETERxV R when manipulated was examined Tampering Effects: Pharmacokinetics of Abuse-Deterrent Oxycodone when ingested in the presence of food, as this is a common form of administration in the intended patient population.
Methods
This was a randomized, open-label, single-dose, fivetreatment, active-controlled, naltrexone-blocked, crossover comparison study. The study was conducted at a single-center in the United States (Hackensack, NJ) in accordance with the International Conference on Harmonization and Good Clinical Practice guidelines, FDA regulations governing clinical study conduct, and the Declaration of Helsinki (and its amendments). Study materials were reviewed by an independent ethics review committee (IntegReview Ethics Review Board, Austin, TX) as required by local regulations. All subjects provided written informed consent after a complete explanation of the study and before any study-related procedures were performed. Subjects were informed that they could discontinue the study at any time.
Subjects
During a standard medical screening visit, potential subjects were evaluated for study eligibility. Subjects were healthy males and females (aged 18-50 years inclusive), with no clinically significant abnormalities on medical history, vital signs, physical examination, 12-lead electrocardiogram, or clinical laboratory tests. Subjects with a history of drug or alcohol abuse were excluded, as were regular users of tobacco products, subjects with intolerance or difficulty with venipuncture, subjects with known allergies to any of the test products, and subjects with a disorder or condition that may have interfered with drug absorption. Subjects were required to have a negative urine drug screen, saliva alcohol test, and urine cotinine test at the Screening visit and at admission to each Treatment Period. To minimize the risk of interaction, subjects were restricted from using other prescription or nonprescription drugs (except acceptable forms of birth control and acetaminophen), herbal remedies, or nutritional supplements during the study. Subjects were also told to avoid caffeine and alcohol for 24 hours prior to admission to each Treatment Period and were to abstain from food containing grapefruit, pomegranate, pomelo, and poppy seeds from 1 week prior to Treatment Period 1 until the end of the study. Female subjects of childbearing potential were required to be nonpregnant and nonlactating, had to use acceptable methods of contraception during the study, and were required to have a negative urine pregnancy test before dosing in each treatment period.
Overall Study Design
This five-way cross-over study included a 21-day Screening Phase, followed by a five-period Treatment Phase in which subjects received single oral doses of intact Oxycodone DETERxV R 40 mg (expressed as HCl equivalents), crushed Oxycodone DETERxV R 40 mg, intact OxyContinV R 40 mg, crushed OxyContinV R 40 mg, and crushed IR oxycodone 40 mg in a randomized order. At each of the five Treatment Periods, subjects were admitted to the research unit the day before dosing at which time they received an oral dose of 50 mg naltrexone (approximately 13 hours prior to dosing) to ensure that they were able to tolerate naltrexone dose. If subjects were able to tolerate the naltrexone, they were given a second 50 mg dose of naltrexone 1 hour prior to study drug dosing as a safety precaution. Subjects were assigned to 1 of 10 treatment sequences according to a two 5 3 5 "Williams Square" randomization design and received one dose of each of the assigned treatments following an overnight fast of at least 10 hours. Subjects started a standardized highfat, high-calorie (HFHC) breakfast (approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively, as per Guidance for Industry: Food Effect Bioavailability and Fed Bioequivalence Studies, 2002) 30 minutes prior to the scheduled dosing time. Subjects were required to consume the meal within 20 minutes. Subjects who were not able to finish their standardized HFHC meal within the allotted time were not dosed and were discontinued from the study. All subjects were required to fast for at least 4 hours following dosing. Subjects were allowed to consume water freely other than 1 hour before and after drug administration.
For Oxycodone DETERxV R and OxyContinV R Treatment Periods, serial blood samples for pharmacokinetic evaluation were collected predose and for 36 hours postdose. For IR oxycodone, pharmacokinetic were collected predose and for 24 hours postdose. Subjects were to be deemed medically stable by the study Investigator prior to discharge. There was a minimum 5-day washout period between each dose of study drug.
Study Drugs
Intact Oxycodone DETERxV R (Collegium Pharmaceutical, Inc., Canton, MA) and intact OxyContinV R (Purdue Pharma, L.P., Stamford, CT) were administered as single 40 mg capsules and tablets, respectively, with 240 mL of non-carbonated, room temperature water.
Crushed Oxycodone DETERxV R and crushed IR oxycodone (administered as 2 3 20 mg tablets; KVK-Tech, Inc., Newtown, PA) were prepared using the same method. Crushed OxyContinV R was prepared using a different crushing method; however, in all cases, the most aggressive methods of reducing the particle size of the respective products was used based on data collected in previously conducted in vitro studies (Figure 1 ) [19] . The dosing procedure for crushed dosage forms was consistent across all three products in this study. Solid, crushed material was transferred in a dry state into the subject's mouth, followed by consumption of water. The dosing cups were then rinsed to ensure all crushed material had been transferred. Study staff conducted a visual oral cavity check to ensure that all study drug had been consumed.
Pharmacokinetic Measures
During each Treatment Period, blood samples for determining plasma oxycodone concentrations were obtained for each subject just prior to dosing and at 0. 25 compound's maximum plasma concentration (C max ) and the time to reach that peak concentration (T max ). It is a measure of rate of rise in plasma concentration; the score is thought to be related to a product's abuse potential with a higher AQ indicating a steeper rise in plasma concentration and consequently a more desirable pharmacodynamic effect for an abuser [20] . Pharmacokinetic parameters were calculated from plasma concentration data using noncompartmental methods (WinNonlin Version 6.3, Pharsight Corporation, St. Louis, MO).
Safety Monitoring
Safety and tolerability evaluations included assessment of treatment-emergent adverse events (TEAEs), monitoring of vital signs, oxygen saturation, physical examinations, and results of clinical laboratory tests.
Pharmacokinetic and Statistical Analyses
Subjects who completed three of the five Treatment Periods, who had sufficient quantifiable plasma Tampering Effects: Pharmacokinetics of Abuse-Deterrent Oxycodone concentration data to provide C max and AUC data and who did not experience emesis within 12 hours of dosing were included in the pharmacokinetic analyses. Subjects who received at least one dose of study drug and for whom there was at least one post-treatment safety observation were included in the safety analyses.
For pharmacokinetic data, an analysis of variance was performed on the ln-transformed AUC last , AUC INF , and C max . The model included sequence, treatment, and period as fixed effects, and subject nested within sequence as a random effect. Bioequivalence was concluded if the 90% confidence intervals (CIs) of the estimated mean ratios fell entirely within the 80.0-125% range (as per FDA guidance) [21] . The primary analyses were a comparison of crushed Oxycodone DETERxV R vs crushed IR oxycodone, and crushed OxyContinV R vs crushed IR oxycodone. Secondary analyses included comparisons of crushed Oxycodone DETERxV R vs intact Oxycodone DETERxV R and crushed OxyContinV R vs intact OxyContinV R ; intact Oxycodone DETERxV R vs crushed IR oxycodone and intact OxyContinV R vs crushed IR oxycodone; and intact Oxycodone DETERxV R vs intact OxyContinV R and crushed Oxycodone DETERxV R vs crushed OxyContinV R .
Safety and tolerability were tabulated descriptively through TEAEs, vital signs measurements, oxygen saturation, and hematologic, biochemical, and urinalysis laboratory parameters.
Results

Subject Disposition and Demographics
Forty-two subjects (32 males and 10 females) were enrolled and randomized to receive study drug; 38 subjects (30 males and 8 females) completed the study. Four subjects were discontinued before completing the Treatment Phase (one subject discontinued because of a positive urine drug screen, one subject did not return to the clinic after Treatment Period 3 and was lost to follow-up, and two subjects were discontinued because they were unable to complete the HFHC meal). The mean (range) age of subjects was 37.7 (23-50) years. Subjects were mostly male (78.9%) and were either white (52.6%) or black/African American (47.4%).
Pharmacokinetics
After oral administration of crushed IR oxycodone with a HFHC meal, there was a rapid initial increase in mean plasma concentrations of oxycodone; C max was reached at approximately 1.75 hours after dosing. Oral administration of crushed OxyContinV R resulted in a similar rapid rise in plasma oxycodone concentrations with a similar C max and T max (Table 1) as the reference IR oxycodone product. In contrast, oral administration of both intact and crushed Oxycodone DETERxV R resulted in a lower and delayed mean C max (T max 3.5 and 4.00 hours, respectively). The rise in plasma oxycodone concentrations was longest following administration of oral intact OxyContinV R , with a mean C max achieved at approximately 5 hours postdose (Figure 2 OxyContinV R was similar to the values observed for crushed IR oxycodone (Figure 2b ).
Statistical results of the comparisons between crushed and intact Oxycodone DETERxV R and between both Oxycodone DETERxV R doses and IR oxycodone are presented in Table 2 . Crushed Oxycodone DETERxV R had lower C max and AUC INF compared with crushed IR oxycodone; the two treatments were not bioequivalent. The median T max was also significantly longer for crushed Oxycodone DETERxV R compared with crushed IR oxycodone (median difference 2.0 hours, P < 0.0001). Peak (C max ) and total (AUC INF ) exposure to oxycodone was similar after oral administration of crushed and intact Oxycodone DETERxV R with the CI and point estimates falling within the 80-125% CI range consistent with the bioequivalence criterion. The median difference in T max between crushed Oxycodone DETERxV R and intact Oxycodone DETERxV R was 0.13 hours and was not statistically different (P 5 0.185).
Crushed OxyContinV R peak and total exposure was similar to crushed IR oxycodone; the two products were bioequivalent based on the CI and point estimates falling within the 80-1.25% range (Table 3) . Crushed OxyContinV R resulted in a substantially higher C max compared with intact OxyContinV R ; as a result, the crushed and intact forms of OxyContinV R were not bioequivalent on this measure, but were bioequivalent on AUC last and AUC INF . The median T max for crushed OxyContinV R did not differ from crushed IR oxycodone (1.75 hours) and was significantly shorter than intact OxyContinV R (median difference 3.25 hours; P < 0.0001).
The highest mean AQ score was observed for crushed IR Oxycodone, followed closely by crushed OxyContinV R (Table 1 ). In contrast, AQ values were markedly lower for intact and crushed Oxycodone DETERxV R treatments as well as intact OxyContinV R . Mean AQ value for crushed OxyContinV R was approximately four-fold higher than that of intact OxyContinV R . Likewise, the AQ value for crushed IR oxycodone was approximately three times greater than those of intact and crushed Oxycodone DETERxV R (Figure 3 ).
Safety and Adverse Events
Single 40 mg oral doses of intact and crushed Oxycodone DETERxV R following a HFHC meal and administered with 50 mg of naltrexone, were generally well- The most common TEAEs (>5%) reported during this study were fatigue (5.3%) following administration of intact Oxycodone DETERxV R and headache following administration of intact Oxycodone DETERxV R (5.3%) and crushed IR oxycodone (7.5%). There were no TEAEs reported following administration of crushed or intact OxyContinV R that were considered related to study drug. Most of the TEAEs reported were relatively transient and of mild to moderate intensity. None of the subjects experienced serious TEAEs and none of the subjects were discontinued from the study due to TEAEs. A summary of TEAEs by treatment is provided in Table 4 . There were no clinically significant treatment-related changes in clinical laboratory results, vital signs, blood oxygen saturations levels or physical examination findings.
Discussion
The Oxycodone DETERxV R formulation has been developed to provide physicians and patients with a novel ER oxycodone ADF without the use of aversive or antagonist agents. The purpose of this study was to evaluate the impact of tampering on the oral pharmacokinetics of the Oxycodone DETERxV R capsule compared with an IR oxycodone and a currently marketed abuse-deterrent formulation of oxycodone, reformulated OxyContinV R , in healthy, naltrexone blocked subjects using the most aggressive tampering method as determined from the results of in vitro manipulation studies [19] .
Manipulation of Oxycodone DETERxV R to its effective limit (i.e., "worst-case scenario") did not significantly change the oxycodone pharmacokinetic profile when compared with intact Oxycodone DETERxV R ; the crushed and intact products were bioequivalent with no significant difference in T max . These results suggest that Oxycodone DETERxV R had its intended effect of maintaining its ER characteristics despite tampering. Consistent with these findings, AQ values were comparable for crushed and intact Oxycodone DETERxV R treatments, and were much lower compared with crushed IR oxycodone.
In contrast, crushing reformulated OxyContinV R resulted in a significantly higher C max and shorter median T max compared with intact OxyContinV R . Moreover, the early plasma exposure profile, as measured by cumulative PAUC up to 1.75 hours, was markedly different for crushed and intact OxyContinV R ; therefore, crushed OxyContinV R was bioequivalent to crushed IR oxycodone, but not to intact OxyContinV R . Although results of this study showed some minor differences in the pharmacokinetic profile between intact Oxycodone DETERxV R and intact OxyContinV R , the two products were bioequivalent on C max , AUC last , and AUC INF.
The safety profile of crushed Oxycodone DETERxV R was similar to that of intact Oxycodone DETERxV R . Overall, all treatments were well-tolerated by study subjects, in part as a result of the naltrexone blockade, and none of the subjects withdrew from the study due to adverse events (AEs).
The goal of most abuse-deterrent opioid technologies is to make tampering more difficult or to make abuse of the product via an unintended route (i.e., intranasal or intravenous) less attractive. For example, products with physicochemical deterrent properties are developed to be very hard or to contain excipients, which gel or clump when mixed with a liquid. Although these characteristics are useful in deterring abuse by the intranasal and intravenous routes, administration can be problematic in the intended patient population. For example, such tablets can be difficult to swallow due to the gelling components becoming sticky on contact with saliva. Many patients with pain, particularly those with dysphagia or odynophagia must consume their medication crushed and with food [22] . While it is possible to physically crush these hard, gelling tablets for oral administration, this practice significantly increases safety risks to patients and contain product warnings related to crushing. For example, the OxyContinV R label states "cutting, breaking, chewing, crushing, or dissolving OxyContinV R impairs the controlled-release delivery mechanism and results in the rapid release and absorption of a potentially fatal dose of oxycodone." This is also the case for agonist/antagonist ADFs such as those which contain a sequestered core of naltrexone (e.g., EmbedaV R ), which, if administered crushed cannot only results in the treatment being ineffective, but can also elicit withdrawal in those patients who are physically dependent on opioids [23, 24] . The current result, which found that crushed Oxycodone DETERxV R was bioequivalent to intact Oxycodone DETERxV R even when administered with food, supports the use of this product as a novel opioidformulation for moderate to severe pain in patients who are unable to swallow solid, oral dosage forms.
Recent epidemiological research suggests that as more ADFs are approved and available to the public, illicit drug users are becoming more adept at defeating the deterrent properties of these formulations. The monitoring of public Internet forums revealed 37 "recipes" for circumventing the AD characteristics of one ADF ER opioid product, 32 of which were deemed feasible [25] . Therefore, from a public health perspective, there is an unmet need for a physicochemical ADF that, if defeated Tampering Effects: Pharmacokinetics of Abuse-Deterrent Oxycodone (i.e., crushed or chewed), still maintains its deterrent properties. Oxycodone DETERxV R has been designed to retain its ER properties following manipulation and as a result deter illicit abuse. While it is still possible to abuse Oxycodone DETERxV R orally by taking multiple capsules intact, it is likely that the ability to retain ER features following manipulation will make it less attractive to abusers compared with existing ADFs.
This study was conducted in line with the FDA guidance recommendations for assessing the pharmacokinetic profile of an abuse deterrent product [26] , including the inclusion of a reference product (IR oxycodone) and an active comparator (OxyContinV R ), and the inclusion of extensive blood sampling time points to appropriately characterize the pharmacokinetic profile when a product is then administered intact and crushed. This study design did not include an assessment of the subjective effects (e.g., "drug-liking" or "desire to take the drug again") of Oxycodone DETERxV R when administered intact and crushed. Subjective measures, particularly the assessment of "at-this-moment'" drug-liking, are considered the most sensitive and face-valid measures of abuse potential [27, 28] . Therefore, a HAL study was recently conducted to investigate whether the maintenance of ER properties in physically manipulated Oxycodone DETERxV R will be sufficient to decrease the positive subjective effects in recreational drug users.
Conclusions
These data demonstrate that on physical manipulation crushed Oxycodone DETERxV R retains its ER profile in contrast to crushed reformulated OxyContinV R ADF, which showed a similar pharmacokinetic profile as crushed IR oxycodone when administered orally. These results suggest that the Oxycodone DETERxV R formulation may be less attractive to illicit drug users compared with existing ADFs, while also providing a novel extended release treatment option for pain patients who have painful or difficulty with swallowing.
